Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-10-07FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental ANDA for methylphenidate hydrochloride by SpecGx LLC. The action formalizes a change under the generic drug appr…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: CBT-I in Adolescents With ADHD [NA]
An ongoing clinical trial evaluating cognitive behavioral therapy for insomnia in adolescents with ADHD; the study is active but not recruit…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Transcranial Photobiomodulation With Multiple Interventions in Children With Attention-Deficit/Hyperactivity Disorder [NA]
This clinical trial update describes a study on transcranial photobiomodulation with multiple interventions in children with Attention-Defic…
-
CLINICAL_TRIALS withdrawal · 2025-10-03Clinical Trial Update: ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder [Phase 4]
A Phase 4 clinical trial evaluating ADZENYS XR-ODT in children aged 4 to under 6 with ADHD has been withdrawn.
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Prevalence of ADHD in Children With Epilepsy
This clinical trial will assess how common ADHD is among children with epilepsy. It is currently not yet recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Where Wild Things Grow: Nature- and Activity-based Group Interventions for Neurodivergent Children and Youth [NA]
Recruiting clinical trial led by Sorlandet Hospital HF evaluating nature- and activity-based group interventions for neurodivergent children…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Effects of Transcranial Photobiomodulation in ADHD [NA]
University of Texas at Austin sponsors a clinical trial evaluating transcranial photobiomodulation for Attention Deficit Hyperactivity Disor…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Evaluation of the LUSHA Digital Application for Children With ADHD - Feasibility Study [NA]
Feasibility study evaluating the LUSHA digital application for children with ADHD; the trial is currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: The Efficacy of a Transdiagnostic Sleep and Circadian Intervention for Patients With Mental Disorders and Sleep Problems [NA]
Completed clinical trial evaluating the efficacy of a transdiagnostic sleep and circadian intervention for adults with depression, bipolar d…
-
FDA approval · 2025-09-26FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Epic Pharma LLC)
FDA granted supplemental approval for a generic Amphetamine Sulfate product by Epic Pharma LLC.
-
FDA approval · 2025-09-23FDA Approved: XELSTRYM — Supplemental Application (Noven Therapeutics, LLC)
FDA approved a supplemental application for XELSTRYM (dextroamphetamine) from Noven Therapeutics, LLC. The action updates the product labeli…
-
FDA approval · 2025-09-23FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
FDA approved a supplemental application for the methylphenidate transdermal system from PADAGIS US LLC.
-
FDA approval · 2025-09-23FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) from Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2025-09-23FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
FDA approved a supplemental application for DYANAVEL XR (amphetamine) submitted by NextWave Pharmaceuticals, Inc. The submission status is A…
-
FDA approval · 2025-09-23FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application from Prasco Laboratories for four amphetamine salt formulations (dextroamphetamine saccharate, a…
-
FDA approval · 2025-09-23FDA Approved: AZSTARYS — Supplemental Application (Corium, LLC.)
The FDA approved a supplemental application for AZSTARYS (serdexmethylphenidate and dexmethylphenidate) by Corium, LLC.
-
FDA approval · 2025-09-23FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) from Takeda Pharmaceuticals America, expanding the approve…
-
FDA approval · 2025-09-23FDA Approved: APTENSIO XR — Supplemental Application (Rhodes Pharmaceuticals L.P.)
The FDA approved a supplemental application for APTENSIO XR, a methylphenidate hydrochloride product from Rhodes Pharmaceuticals L.P. The ap…
-
FDA approval · 2025-09-23FDA Approved: COTEMPLA XR-ODT — Supplemental Application (Neos Therapeutics Brands, LLC)
FDA approved a supplemental application for Cotempla XR-ODT (methylphenidate) from Neos Therapeutics Brands, LLC, expanding or updating the …
-
FDA approval · 2025-09-23FDA Approved: QUILLIVANT XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for Quillivant XR (methylphenidate hydrochloride) from NextWave Pharmaceuticals, Inc.
-
FDA approval · 2025-09-23FDA Approved: DEXEDRINE SPANSULE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA granted a supplemental approval for Dexedrine Spansule (dextroamphetamine sulfate) to Amneal Pharmaceuticals LLC.
-
FDA approval · 2025-09-23FDA Approved: QUILLICHEW ER — Supplemental Application (NextWave Pharmaceuticals, Inc)
FDA approved a supplemental application for Quillichew ER (methylphenidate hydrochloride) submitted by NextWave Pharmaceuticals, Inc.
-
FDA approval · 2025-09-23FDA Approved: AMPHETAMINE EXTENDED-RELEASE — Supplemental Application (Neos Therapeutics, LP)
FDA approved a supplemental application for AMPHETAMINE EXTENDED-RELEASE from Neos Therapeutics, LP, indicating updated labeling/indication …
-
FDA approval · 2025-09-23FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for methylphenidate from Sandoz Inc, updating the product's approval under the existing NDA.
-
FDA approval · 2025-09-23FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for DYANAVEL XR (amphetamine) by NextWave Pharmaceuticals, expanding the approved use under the …